ENSC earnings: next report 2026-08-12, real EPS beat/miss history, analyst consensus Buy, P/E -0.08. Updated 2026-07-23.
Ensysce Biosciences (ENSC) Research Hub
Ensysce Biosciences (ENSC) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 0.4869 USD (+2.63%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -0.08, market cap 0.00B. This hub links to the full technical, earnings and options research available for ENSC.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 0.4869 USD (+2.63%) |
| 52-week range | 0.24 USD – 0.979 USD |
| Trend regime | Range |
| 14-day RSI | 45.7 (Neutral) |
| Trailing P/E | -0.08 |
| Market cap | 0.00B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-12 |
Available research for ENSC
Covered Call on ENSC: how it works, illustrative setup around the real 0.4869 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on ENSC: how it works, illustrative setup around the real 0.4869 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on ENSC: how it works, illustrative setup around the real 0.4869 USD price, max profit/loss, breakeven and when to use it. Educational.
ENSC technical analysis: range, last 0.4869 USD, RSI 45.7, 52w range 0.24 USD–0.979 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is ENSC in?
Ensysce Biosciences (ENSC) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is ENSC in an uptrend or downtrend?
As of 2026-09-11, ENSC is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is ENSC's trailing P/E ratio?
ENSC's trailing P/E is -0.08, with a market cap of 0.00B. See the earnings research page for full valuation detail.
When does ENSC next report earnings?
ENSC is next scheduled to report earnings on 2026-08-12, with a consensus EPS estimate of -0.5 USD.